Promising new immunotherapies aim to replace harsh chemo for kids with leukemia
NCT ID NCT07476729
First seen May 04, 2026 · Last updated May 04, 2026
Summary
This study tests whether newer, targeted immunotherapy drugs (like inotuzumab and blinatumomab) can replace harsh chemotherapy for children whose B-cell acute lymphoblastic leukemia has returned. About 750 children and teens will receive these less toxic treatments to see if they improve survival and reduce side effects. The goal is to make these immunotherapies the new standard of care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acıbadem University
Istanbul, 34752, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de NICE, Hôpital L'ARCHET
Nice, 06202, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fakultni Nemocnice V Motole
Prague, 150 00, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fundeni Clinical Institute, Pediatric Clinic Fundeni
Bucharest, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ghent University Hospital
Ghent, B-9000, Belgium
Contact
-
HUS Helsinki University Hospital
Helsinki, FIN-00290, Finland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto Português de Oncologia de Lisboa
Lisbon, 1099-023, Portugal
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karolinska University Hospital
Solna, 171 64, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ospedale Pediatrico Bambino Gesu
Rome, 00165, Italy
Contact
-
Prinses Máxima Centrum
Utrecht, 3584 CS, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rigshospitalet
Copenhagen, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Semmelweis University
Budapest, 1094, Hungary
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Anna Kinderspital GmbH
Vienna, 1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tel Aviv Sourasky Medical Centre Dana-Dwek Children's Hospital
Tel Aviv, 64239, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Children's Hospital
Zurich, 8032, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Clinical Hospital Virgen De La Arrixaca
Murcia, 30120, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Medical Centre Ljubljana
Ljubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Wroclaw
Wroclaw, 50 354, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Univerzity Komenského a Národného
Bratislava, 833 40, Slovakia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.